|
Comments (Ovary, Fallopian Tube)
|   |
|
Comments (Ovary, Fallopian Tube)
| |
Response Options to “Histologic Type”
___ Serous tubal intraepithelial carcinoma (STIC)
___ Serous borderline tumor/atypical proliferative serous tumor
___ Serous borderline tumor/atypical proliferative serous tumor with microinvasion
___ Serous borderline tumor-micropapillary variant/noninvasive low-grade serous carcinoma
___ Serous carcinoma
___ Endometrioid borderline tumor/atypical proliferative endometrioid tumor
___ Endometrioid borderline tumor/atypical proliferative endometrioid tumor with microinvasion
___ Endometrioid carcinoma
___ Clear cell borderline tumor/atypical proliferative clear cell tumor
___ Clear cell carcinoma
___ Mucinous borderline tumor/atypical proliferative mucinous tumor
___ Mucinous borderline tumor/atypical proliferative mucinous tumor with intraepithelial carcinoma
___ Mucinous borderline tumor/atypical proliferative mucinous tumor with microinvasion
___ Mucinous carcinoma
+ ___ Mucinous carcinoma with expansile invasive pattern
+ ___ Mucinous carcinoma with infiltrative invasive pattern
___ Seromucinous borderline tumor/atypical proliferative seromucinous tumor
___ Seromucinous borderline tumor/atypical proliferative seromucinous tumor with microinvasion
___ Seromucinous carcinoma
___ Brenner tumor, borderline/atypical proliferative Brenner tumor
___ Brenner tumor, malignant
___ Carcinoma, subtype cannot be determined
___ Mixed epithelial borderline (atypical proliferative) tumor (specify types and percentages): ______________
___ Mixed epithelial carcinoma (specify types and percentages): ________________________
___ Carcinosarcoma (malignant mixed Müllerian tumor)
___ Small cell carcinoma, pulmonary type
___ Small cell carcinoma, hypercalcemic type
___ Squamous cell carcinoma
___ Transitional cell carcinoma
___ Undifferentiated carcinoma
___ Granulosa cell tumor, adult type
___ Granulosa cell tumor, juvenile type
___ Other sex cord-stromal tumor (specify type): ________________________
___ Dysgerminoma
___ Yolk sac tumor (endodermal sinus tumor)
___ Immature teratoma
___ Carcinoma arising from a teratoma (specify type): _______________
___ Mixed malignant germ cell tumor (specify types and percentages): ________________________
___ Other histologic type not listed (specify): ________________________
**Note: Histologic grade is required for serous, endometrioid, mucinous, and seromucinous carcinomas, immature teratomas, and Sertoli-Leydig cell tumors. Serous carcinomas are graded via a 2-tier system (low grade/high grade). Immature teratomas can be graded using a 2-tier or 3-tier system. Endometrioid and mucinous carcinomas are graded via a 3-tier system (well differentiated/moderately differentiated/poorly differentiated). Sertoli-Leydig cell tumors are graded via a modified 3-tier grading system with grade 2 tumors being termed “intermediate differentiated.” Clear cell carcinomas, borderline epithelial neoplasms, all other malignant sex-cord stromal and germ cell tumors are not graded.
***Note: Required for advanced stage serous/seromucinous borderline tumors only. Serous tumor implants that were formerly classified as “invasive implants” are now classified as low-grade serous carcinoma of the peritoneum.
Response Options to “Other Tissue/ Organ Involvement” (select all that apply)
___ Not applicable
___ Not identified
___ Right ovary
___ Left ovary
___ Ovary (side not specified)
___ Right fallopian tube
___ Left fallopian tube
___ Fallopian tube (side not specified)
___ Uterus
___ Cervix
___ Pelvic peritoneum
___ Abdominal peritoneum
___ Omentum
___ Other organs/tissue (specify): ________________
___ Cannot be determined (explain):_________________________
Response Options to “Treatment Effect” (required only for high-grade serous carcinomas)
Note: Treatment effect is based on assessment of residual tumor in the omentum.
___ No known presurgical therapy
___ No definite or minimal response identified (chemotherapy response score 1 [CRS 1])
___ Moderate response identified (CRS 2)
___ Marked response with no or minimal residual cancer (CRS 3)
___ Cannot be determined
****Note: For ovarian, fallopian tube, or primary peritoneal tumors, lymph nodes designated as pelvic, external iliac, internal iliac (hypogastric), common iliac, parametrial, obturator, sacral, presacral, para-aortic, and retroperitoneal are considered regional lymph nodes. Although not specifically named by AJCC or FIGO, intra-omental and peri-intestinal lymph nodes, are also regarded as regional lymph nodes for staging purposes. Any other involved nodes should be categorized as metastases (pM1) and commented on in the distant metastasis section. Presence of isolated tumor cells no greater than 0.2 mm in regional lymph node(s) is considered N0 (i+). Reporting the number of lymph nodes with isolated tumor cells is required only in the absence of metastasis greater than 0.2 mm in other lymph nodes.